The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer.
 
Andrei Gafita
No Relationships to Disclose
 
Loic Djaileb
No Relationships to Disclose
 
Isabel Rauscher
No Relationships to Disclose
 
Wolfgang P. Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Accord Healthcare; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Ipsen; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; Pfizer; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Ipsen; Janssen
 
Steven P. Rowe
Stock and Other Ownership Interests - PlenaryAI; Precision Molecular
Consulting or Advisory Role - Precision Molecular
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - PlenaryAI; Precision Molecular
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics
 
Matthew Rettig
Leadership - Aravalent; Survalent
Stock and Other Ownership Interests - Oncovalent Therapeutics; Survalent
Consulting or Advisory Role - Ambrx; Amgen; INMune Bio; Precisca; Roivant
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Arvinas (Inst); Fortis (Inst); Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Matthias Eiber
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Janssen; Novartis; POINT Biopharma; RayzeBio; Telix Pharmaceuticals
Speakers' Bureau - Janssen
Research Funding - Blue Earth Diagnostics
Patents, Royalties, Other Intellectual Property - rhPSMA
 
Manuel Weber
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis
Speakers' Bureau - Boston Scientific; Lilly; Terumo
 
Matthias R. Benz
No Relationships to Disclose
 
Andrea Farolfi
No Relationships to Disclose